JPH10236955A - Therapeutic agent for common acne containing adrenocortical steroid as active ingredient - Google Patents

Therapeutic agent for common acne containing adrenocortical steroid as active ingredient

Info

Publication number
JPH10236955A
JPH10236955A JP7875997A JP7875997A JPH10236955A JP H10236955 A JPH10236955 A JP H10236955A JP 7875997 A JP7875997 A JP 7875997A JP 7875997 A JP7875997 A JP 7875997A JP H10236955 A JPH10236955 A JP H10236955A
Authority
JP
Japan
Prior art keywords
acne
adrenocortical steroid
active ingredient
common acne
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7875997A
Other languages
Japanese (ja)
Inventor
Kazunori Yamamoto
和徳 山元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP7875997A priority Critical patent/JPH10236955A/en
Publication of JPH10236955A publication Critical patent/JPH10236955A/en
Pending legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROBLEM TO BE SOLVED: To prepare a therapeutic agent capable of rapidly exterminating common acne by including an adrenocortical steroid therein. SOLUTION: This therapeutic agent for common acne comprises an adrenocortical steroid as an active ingredient. An antimicrobial substance as an auxiliary agent and further a lactic acid fermentation product as an auxiliary ingredient can be contained therein. Cortisone, prednisone, etc., are cited as the adrenocortical steroid and the adrecortical steroid agent is preferably contained in an amount of 0.04-0.07 mg based on 1g base. Although the adrenocortical steroid has hitherto never been used for treating the common acne at all, bacteria on the skin surface and Propionibacterium acnes living in depth can be sterilized to prevent the formation of free fatty acids with the lipase thereof. Thereby, the generation of the common acne can be suppressed. Since the amount of the adrenocortical steroid used is extremely small, there is no fear of inducing infectious diseases or causing other side effect.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【産業上の利用分野】本発明は、副腎皮質ステロイドを
有効成分とするニキビ治療薬、副腎皮質ステロイドを有
効成分とし、抗菌性物質を補助剤とするニキビ治療薬、
副腎皮質ステロイドを有効成分とし、乳酸発酵生成物を
補助成分とするニキビ治療薬、及び副腎皮質ステロイド
を有効成分とし、抗菌性物質を補助剤とするとともに乳
酸発酵生成物を補助成分とすることを特徴とするニキビ
治療薬に関する。
The present invention relates to a remedy for acne comprising a corticosteroid as an active ingredient, a remedy for acne comprising a corticosteroid as an active ingredient and an antibacterial substance as an adjuvant,
Acne treatments with corticosteroids as active ingredients and lactic acid fermentation products as auxiliary ingredients, and corticosteroids as active ingredients, antibacterial substances as adjuvants and lactic acid fermentation products as auxiliary ingredients. The invention relates to a remedy for acne.

【0002】[0002]

【従来の技術】これまでニキビの対策あるいは治療法と
しては、硫黄、レゾルシン、フエノールを有効成分とす
る皮膚の表面の細菌類を殺菌するニキビ治療薬を用いる
ものであった。
2. Description of the Related Art Hitherto, as an acne countermeasure or treatment, an acne remedy for killing bacteria on the surface of skin containing sulfur, resorcin, and phenol as active ingredients has been used.

【0003】[0003]

【発明の解決すべき課題】ニキビ症対策の一つとして
は、主として硫黄、レゾルシン、フェノール、抗生物質
その他の抗菌性物質をニキビに塗布し、ニキビの上皮に
生息している細菌類を殺菌、除去することによって行わ
れている。しかし、それらの効果は抗菌作用の消失によ
って細菌類が再び定着するまでの一時的なものにすぎ
ず、ニキビの根絶治療は不可能であった。ニキビの発生
原因として、細菌類が産生するリパーゼが、脂線で生成
された脂質を分解して生成した遊離脂肪酸がヒトの皮膚
に対して炎症を引き起こすと言われているが、それに対
する反論が有る。本発明者は、生態組織でのニキビの発
生原因となる生成物質の合成抑制とそれらの分泌抑制を
主な作用とするニキビの治療法の開発に努め、ニキビを
迅速に根絶させることができる治療薬の開発に力を注い
できた。
One of the measures against acne is to apply mainly sulfur, resorcinol, phenol, antibiotics and other antibacterial substances to acne to kill bacteria that inhabit the acne epithelium. It has been done by removing. However, their effects were only temporary until the bacteria re-established due to the loss of antibacterial activity, and acne eradication treatment was not possible. As a cause of acne, it is said that lipase produced by bacteria breaks down lipids produced by the grease and the free fatty acids produced cause irritation to human skin. Yes. The present inventor has been working on the development of a method for treating acne whose main function is to suppress the synthesis of a substance that causes acne in ecological tissues and to suppress their secretion, and to treat eczema quickly. Focused on drug development.

【0004】[0004]

【課題を解決するための手段】本発明の第一の構成は、
副腎皮質ホルモンを有効成分として含有することを特徴
とするニキビ治療薬である。本発明の第二の構成は、副
腎皮質ホルモンを有効成分とし、抗菌性物質を補助剤と
して含有することを特徴とするにニキビ治療薬である。
本発明の第三の構成は、副腎皮質ステロイドを有効成分
とし、乳酸発酵生成物を補助成分とすることを特徴とす
るニキビ治療薬、及び本発明の第四の構成は、副腎皮質
ステロイドを有効成分とし、抗菌性物質を補助剤とする
とともに乳酸発酵生成物を補助成分とすることを特徴と
するニキビ治療薬である。本発明において有効成分とし
て用いる副腎皮質ステロイドとしては、例えばコーチゾ
ン、コーチゾール、ハイドロコーチゾン、酢酸コーチゾ
ン、酢酸ヒドロコーチゾンなどのコーチゾン製剤、プレ
ドニゾロン、メチルプレドニゾロン、コハク酸プレドニ
ゾロンナトリウム、酢酸プレドニゾロン、ブチル酢酸プ
レドニゾロンなどのプレドニゾロン製剤、プレドニゾ
ン、メチルプレドニゾン、トリアムシノロン、テキサメ
サゾン、パラメサゾン、ベータメサゾンなど公知のもの
から選択することができる。ニキビ症に対してニキビに
副腎皮質ステロイドを塗布する際には、補助剤として一
種又は二種以上の殺菌剤又は抗菌性物質を併用してニキ
ビの上皮に生息している細菌類を殺菌するか又はそれら
の活動を抑制するのが望ましい。上記の補助剤は従来の
ニキビ治療剤における殺菌剤、抗菌剤自体の機能もある
が、その併用によってむしろ有効成分である副腎皮質ス
テロイド類のニキビ抑制効果をより少ない副腎皮質ステ
ロイド類の投与量で有効に達成することができる。上記
の殺菌剤又は抗菌剤としては上記上皮ステロイド類を含
む分泌物を代謝する細菌類に対して殺菌作用又は抗菌作
用を奏する抗生物質又は化学殺菌剤の中から選択するこ
とができる。副腎皮質ステロイド剤によるニキビ症の治
療効果は極めて顕著かつ迅速であり、基剤1グラムに対
して約2mg以下の副腎皮質ステロイド類を含有する本
発明のワキガ治療薬をニキビの上皮に一ないし二回塗布
することによってほとんどの場合、完全な治癒に至る。
プロピオニバクテリウム・アクネスは、毛漏斗に常在菌
として生息しているので、ニキビの発生に関与している
ものと考えられる。本発明のニキビ治療薬の下限の有効
投与量について、ニキビの原因と考えられるプロピオニ
バクテリウム・アクネスに対して感受性テストを行った
結果、微量ですでに有意の結果が得られた。この成果に
基づいて実際のニキビ症患者の治療有効量を臨床的試験
によって追跡したところ、基剤1gに対して副腎皮質ス
テロイド剤を0.02mg以上、好ましくは約0.04
〜0.07mgを含むことが望ましい。
Means for Solving the Problems A first structure of the present invention is as follows.
It is a remedy for acne, comprising a corticosteroid as an active ingredient. A second aspect of the present invention is a remedy for acne, which is characterized by containing a corticosteroid as an active ingredient and an antibacterial substance as an auxiliary.
A third configuration of the present invention is a remedy for acne characterized by using a corticosteroid as an active ingredient and a lactic acid fermentation product as an auxiliary component, and a fourth configuration of the present invention is effective for using a corticosteroid. An acne remedy characterized by comprising, as an ingredient, an antibacterial substance as an adjuvant and a lactic acid fermentation product as an adjunct ingredient. The corticosteroid used as an active ingredient in the present invention includes, for example, cortisone, cortisol, hydrocortisone, cortisone acetate, cortisone preparations such as hydrocortisone acetate, prednisolone, methylprednisolone, prednisolone sodium succinate, prednisolone acetate, prednisolone butyl acetate and the like , Prednisone, prednisone, methylprednisone, triamcinolone, texamethasone, paramethasone, betamethasone and the like. When applying corticosteroids to acne for acne disease, do one or two or more bactericides or antibacterial substances be used as adjuvants to kill bacteria that inhabit the acne epithelium? Or it is desirable to suppress those activities. The above-mentioned adjuvant also has the function of a bactericide in the conventional acne treatment agent, the antibacterial agent itself, but the combined use of the adjuvant suppresses the acne-suppressing effect of the corticosteroid, which is an active ingredient, with a smaller dose of a corticosteroid. Can be achieved effectively. The bactericide or antibacterial agent can be selected from antibiotics or chemical bactericides that exhibit bactericidal or antibacterial action against bacteria that metabolize secretions including the epithelial steroids. The effect of corticosteroids on the treatment of acne is extremely remarkable and rapid. One of the therapeutic agents of the present invention containing about 2 mg or less of corticosteroids per gram of the base is applied to the epithelium of acne one to two times. Multiple applications often lead to complete healing.
Since Propionibacterium acnes lives as a resident bacterium in the hair funnel, it is considered to be involved in acne development. The lower limit effective dose of the therapeutic agent for acne of the present invention was subjected to a susceptibility test for Propionibacterium acnes, which is considered to be the cause of acne, and as a result, significant results were already obtained in a small amount. Based on this result, the actual therapeutically effective amount of acne patients was traced by a clinical test. As a result, a corticosteroid was used in an amount of 0.02 mg or more, preferably about 0.04 mg / g of the base.
Desirably, it contains 〜0.07 mg.

【0005】[0005]

【作用】従来、副腎皮質ステロイドはニキビの治療には
全く用いられたことがなく、ニキビに対する薬理作用も
必ずしも明らかではないが、副腎皮質ステロイドが、皮
膚面の細菌類のみならず、深部に生息するプロピオニウ
ム アクネス(P.acnes)をも殺菌し、そのリパ
ーゼによる遊離脂肪酸の生成を阻止するため、ニキビ発
生が抑制されるものと推定される。
[Action] Conventionally, corticosteroids have never been used in the treatment of acne, and the pharmacological action on acne is not always clear. However, corticosteroids inhabit not only bacteria on the skin surface but also deeply. Propionium acnes (P. acnes) is also sterilized, and the production of free fatty acids by its lipase is prevented, so that it is presumed that acne generation is suppressed.

【0006】[0006]

【実施例1】本発明をニキビ症患者に対する臨床試験結
果によって説明する。被験患者約170人に対し、基剤
1gに副腎皮質ステロイドとしてプレゾニゾロン2m
g、抗生物質として硫酸フラジオマイシン3mgを含む
軟膏形態の治療薬剤を一日一回ニキビに塗布した。17
0人のほとんどの患者には一回の塗布で顕著な効果があ
らわれ、その他の患者についても二回までの塗布で完全
な治療効果が認められた。副腎皮質ステロイドとしてメ
チルプレドニゾロン、およびコーチゾンを用いたニキビ
症患者に対する臨床試験でもほぼ同様の治療効果が認め
られた。本発明のニキビ治療薬は、副腎皮質ステロイド
剤の使用量は極めて少量であり、感染症の誘発やその他
の副作用を生じる恐れは殆どなく、また長期にわたり連
用の必要がないので、投与による副作用は全く認められ
ていない。
EXAMPLE 1 The present invention will be explained by the results of clinical tests on acne patients. For about 170 test patients, presonisolone 2m was used as a corticosteroid in 1g of the base.
g. A treatment drug in the form of an ointment containing 3 mg of fradiomycin sulfate as an antibiotic was applied to acne once a day. 17
Most of the 0 patients showed a remarkable effect with one application, and the other patients showed a complete therapeutic effect with up to two applications. Almost the same therapeutic effects were observed in clinical trials for acne patients using methylprednisolone and cortisone as corticosteroids. The remedy for acne of the present invention uses a very small amount of corticosteroids, is unlikely to cause infections or cause other side effects, and does not require long-term continuous use. Not at all.

【0007】[0007]

【試験例】[Test example]

プロピオニバクテリウム・アクネスの副腎皮質ステロイ
ド剤に対する感受性テスト 継代培養した試験菌を増菌用培地に接種し、35℃、4
8時間嫌気下で培養した後、培養液を菌数が約10
ml増菌用培地で希釈し、菌体1白金耳量をGAMブイ
ヨン「日水製薬(株)」に移植し、35℃で24時間嫌
気下で培養して接菌用菌液とした。GAM寒天培地「日
水製薬(株)」を入れた各シャーレに対して、上記菌液
を菌数が約10/mlとなるように15mlづつ分注
して固定した。ついで基剤クリーム1gに対して副腎皮
質ステロイド剤としてプレドニゾロンを5mg含む試験
片を同一の基剤クリームによってさらに1、7、28、
280、2800、28000倍に段階的に希釈した希
釈軟膏(有効成分濃度:28000、 4000、 1
000、 100、10および1ppm)を調整した。
検体希釈軟膏を乾熱滅菌した直径10mmのペーパーデ
ィスクに5mg塗布し、試験片とした。 試験片の塗布
面が培地表面と接触するように試験用平板培地の中央に
載せ、35℃で嫌気下で48時間培養後、ハローの有無
を肉眼観察により判定した。表1は、試験片の試験菌p
ropionibacterium acnesに対す
るハロー(発育阻止帯)の有無による抗菌力試験結果を
表す。前記試験結果からワキガ症患者に対する副腎皮質
ステロイド剤の有効投与量を求めた。基剤としての軟膏
クリーム1g中にプレジニゾロンを前記感受性テストで
ハロー円の形成が認められた最小発育阻止濃度(希釈倍
数280:5mg/280)にほぼ対応する0.02m
g/gの量で含むニキビ治療剤を一回,ニキビに塗布し
た。170人の患者について改善が認められたが、症状
によっては一旦軽減したが、一週間の間に再発する例が
認められ、この塗布濃度はある程度有効であるが、症状
によっては必ずしも十分ではなかった。プレドニドロン
の塗布濃度をさらに0.04〜0.07mg/gに増加
させて同様の塗布治療を行ったところ、0.04mg/
gの投与でほとんどの場合において治療効果が得られ、
また0.07mg/gの投与でも前記の0.04mg/
gの投与の場合と変わらない効果が得られた。すなわち
0.04mg/gの一回の塗布によって、約2mg/g
以下の前記有効成分の一ないし二回の投与と同様に、ニ
キビ症の治療効果がが認められた。
Test for susceptibility of Propionibacterium acnes to corticosteroids Subcultured test strains were inoculated into enrichment medium,
After cultivation under anaerobic conditions for 8 hours, the culture solution was adjusted to about 10 6 /
The mixture was diluted with a culture medium for enrichment, and one loopful of cells was transplanted into GAM broth "Nissui Pharmaceutical Co., Ltd." and cultured at 35 ° C. for 24 hours under anaerobic conditions to obtain a bacterial solution for inoculation. The above bacterial solution was dispensed in 15 ml portions to each petri dish containing GAM agar medium “Nissui Pharmaceutical Co., Ltd.” so that the number of bacteria was about 10 6 / ml, and fixed. Then, a test piece containing 5 mg of prednisolone as a corticosteroid per 1 g of the base cream was further added to the same base cream for 1, 7, 28,
A diluted ointment that is serially diluted 280, 2800, 28000 times (active ingredient concentration: 28,000, 4000, 1
000, 100, 10 and 1 ppm).
5 mg of the sample dilution ointment was applied to a dry and heat-sterilized paper disc having a diameter of 10 mm to prepare a test piece. The test piece was placed on the center of the test plate medium so that the coated surface of the test piece was in contact with the surface of the medium, and cultured at 35 ° C. for 48 hours under anaerobic conditions. Table 1 shows the test bacteria p of the test piece.
3 shows the results of an antibacterial activity test on the presence of a halo (growth inhibition zone) against R. ropionobacterium acnes. From the test results, the effective dose of corticosteroids for patients with squirrels was determined. Predinisolone was added to 1 g of an ointment cream as a base at 0.02 m corresponding to the minimum growth inhibitory concentration (dilution factor 280: 5 mg / 280) at which the formation of a halo circle was observed in the sensitivity test.
The acne treatment containing g / g was applied once to the acne. Improvement was observed in 170 patients, but the symptoms were reduced once, but recurred in one week. This application concentration was effective to some extent, but was not always sufficient for some symptoms. . When the same application treatment was performed by further increasing the application concentration of prednidron to 0.04 to 0.07 mg / g, 0.04 mg /
In most cases, a therapeutic effect is obtained by administration of g,
In addition, the above 0.04 mg / g
The same effect as in the case of administration of g was obtained. That is, about one application of 0.04 mg / g gives about 2 mg / g.
As in the following one or two administrations of the active ingredient, a therapeutic effect for acne was observed.

【0008】[0008]

【表1】 [Table 1]

【0009】[0009]

【発明の効果】第一の本発明によれば、従来根治が困難
であったニキビ症に対して副腎皮質ステロイド剤の微量
投与によって著しい治療効果を奏することができる。更
に、第二の本発明によれば、従来根治が困難であったニ
キビ症に対して抗菌剤を併用すれば、副腎皮質ステロイ
ド剤の微量投与によって著しい治療効果を奏するととも
に薬効期間を更に長くすることができる。第三の本発明
によれば、ニキビ症に対して乳酸発酵生成物を併用すれ
ば副腎皮質ステロイド剤の副作用が発生することなく長
期に使用できる。第四の本発明によれば、ニキビ患部の
表面の細菌類を殺菌し、プロピオニバクテリウム アク
ネスのような皮膚内部の細菌類をも殺菌するとともに、
ニキビによる傷跡を修復し、副腎皮質ステロイド剤の投
与量を少なくでき、著しい治療効果を奏し、その薬効期
間を更に長くすることができ、副腎皮質ステロイド剤の
副作用が発生することなく長期に使用できる。
According to the first aspect of the present invention, a remarkable therapeutic effect can be obtained by treating a small amount of a corticosteroid with respect to acne which has been difficult to cure. Furthermore, according to the second aspect of the present invention, when an antibacterial agent is used in combination for acne disease, which has been conventionally difficult to cure, a remarkable therapeutic effect can be obtained by a small amount of administration of a corticosteroid and the drug effect period is further extended. be able to. According to the third aspect of the present invention, the combined use of a lactic acid fermentation product for acne can be used for a long time without causing the side effects of corticosteroids. According to the fourth invention, bacteria on the surface of the acne affected area are sterilized, and bacteria inside the skin such as Propionibacterium acnes are also sterilized,
Repairs scars caused by acne, reduces the dose of corticosteroids, produces a remarkable therapeutic effect, prolongs the duration of the drug, and can be used for a long time without causing side effects of corticosteroids .

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 副腎皮質ステロイドを有効成分とするこ
とを特徴とするニキビ治療薬。
1. A remedy for acne comprising a corticosteroid as an active ingredient.
【請求項2】 副腎皮質ステロイドを有効成分とし、抗
菌性物質を補助剤とすることを特徴とするニキビ治療
薬。
2. A remedy for acne, comprising a corticosteroid as an active ingredient and an antibacterial substance as an adjuvant.
【請求項3】 副腎皮質ステロイドを有効成分とし、乳
酸発酵生成物を補助成分とすることを特徴とするニキビ
治療薬。
3. A remedy for acne, comprising a corticosteroid as an active ingredient and a lactic acid fermentation product as an auxiliary ingredient.
【請求項4】 副腎皮質ステロイドを有効成分とし、抗
菌性物質を補助剤とするとともに乳酸発酵生成物を補助
成分とすることを特徴とするニキビ治療薬。
4. A remedy for acne, comprising a corticosteroid as an active ingredient, an antibacterial substance as an adjuvant, and a lactic acid fermentation product as an auxiliary ingredient.
JP7875997A 1997-02-24 1997-02-24 Therapeutic agent for common acne containing adrenocortical steroid as active ingredient Pending JPH10236955A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP7875997A JPH10236955A (en) 1997-02-24 1997-02-24 Therapeutic agent for common acne containing adrenocortical steroid as active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7875997A JPH10236955A (en) 1997-02-24 1997-02-24 Therapeutic agent for common acne containing adrenocortical steroid as active ingredient

Publications (1)

Publication Number Publication Date
JPH10236955A true JPH10236955A (en) 1998-09-08

Family

ID=13670838

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7875997A Pending JPH10236955A (en) 1997-02-24 1997-02-24 Therapeutic agent for common acne containing adrenocortical steroid as active ingredient

Country Status (1)

Country Link
JP (1) JPH10236955A (en)

Similar Documents

Publication Publication Date Title
JP6625677B2 (en) Calcium flux agonist and method thereof
Rebora et al. Experimental infection with Candida albicans
JPH02501739A (en) steroid lotion
DE1642578C3 (en) Process for the preparation of an enzymatic composition having proteolytic enzyme and collagenase activity
JP2001517199A (en) Nisin in combination with glycerol monolaurate having anti-Helicobacter activity
US9662356B1 (en) Propolis-metal nanoparticle composition and methods of use
US20170072024A1 (en) Antimicrobial composition comprising a carbohydrate, glucose oxidase and zinc oxide
JP2018536010A (en) Activated stem cells and systemic treatment for infected wounds
JP2016522801A (en) Methods and compositions for wound healing
RU2537023C2 (en) Cream for medical application containing fusidic acid prepared with using sodium fusidate and containing biopolymer, and method for preparing it
Jacobsen Topical Wound Treatments and Wound‐Care Products
Orafidiya et al. An investigation into the wound-healing properties of essential oil of Ocimum gratissimum linn
US11759484B2 (en) Compositions and uses thereof
JPH10236955A (en) Therapeutic agent for common acne containing adrenocortical steroid as active ingredient
US6964783B1 (en) Non-solid composition for local application
KR20020044851A (en) Sphingolipid composition for preventing or treating acnes
RU1837870C (en) Method for producing suspension-emulsion of primycin
KR100341172B1 (en) Remedy for axillary osmidrosis containing adrenocorticosteriodal preparation
Haleblian Bioassays used in development of topical dosage forms
US20090317364A1 (en) Novel compositions for prevention and treatment of mastitis and metritis
WO2015168741A1 (en) Extended shelf life wound healing formulation
Acharya et al. Antituberculous activity of a phenazine derivative (B663)
EP1663195A2 (en) Taurine bromamine for inhibiting pathogenic bacteria and fungi growth as well as in a microbicidal composition
EP3585367A1 (en) Cineole-containing composition for treating nasal diseases
JP7253128B2 (en) External composition containing depsipeptide antibiotic